doi:10.3969/j.issn.1673-8640.2022.02.020

Abstract

CLC Number:

R446.1

Figures/Tables 2

References 7

[1]	张静静, 吕荣祥, 刘郁, 等. 老年急性脑梗死患者血尿酸、凝血功能、炎症因子和血液流变学指标的变化[J]. 中国老年学杂志, 2018, 38(8):1815-1817.
[2]	王渊铭, 陈德, 马依彤, 等. 急性缺血性心脑血管疾病TF、TFPI、FⅦ因子及比值的表达[J]. 血栓与止血学, 2017, 23(1):1-5.
[3]	陈小敏, 周小莉, 丁砚兵. 丁苯酞注射液治疗急性脑梗死的临床疗效及定量脑电图分析[J]. 中国卒中杂志, 2018, 13(3):247-250.
[4]	孙凡, 刘恒, 徐倩倩, 等. 依达拉奉对急性脑梗死的疗效及其对出血性转化的影响[J]. 中国现代医学杂志, 2019, 29(3):78-82.
[5]	王金成, 姜立刚, 李海平, 等. 急性脑梗死患者血清正五聚体蛋白3、C反应蛋白水平变化及临床意义[J]. 中国老年学杂志, 2018, 38(1):71-73.
[6]	许位, 张园园, 高敬华, 等. 急性脑梗死患者血清sdLDL-C与PTX-3水平与颈动脉粥样硬化斑块性质的关系[J]. 中风与神经疾病杂志, 2019, 36(8):704-707.
[7]	熊石龙, 王前, 郑磊, 等. 急性缺血性心脑血管疾病组织因子途径的改变[J]. 解放军医学杂志, 2008, 33(1):93-95.

组别	例数	CXCL12/（ng/mL）	PTX-3/（μg/mL）	FⅦa/FⅦAg比值/%	DTABR
急性脑梗死组	112	8.32±1.25^*	1.96±0.58^*	0.94±0.27^*	7.35±2.16^*
正常对照组	30	6.49±0.98	1.35±0.42	0.75±0.15	6.52±0.94

组别	例数	CXCL12/（ng/mL）	PTX-3/（μg/mL）	FⅦa/FⅦAg比值/%	DTABR
急性脑梗死组	112	8.32±1.25^*	1.96±0.58^*	0.94±0.27^*	7.35±2.16^*
正常对照组	30	6.49±0.98	1.35±0.42	0.75±0.15	6.52±0.94

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 7

Related Articles 15

Recommended Articles

Metrics